Guidelines on the use and monitoring of heparin.

GUIDELINE TITLE
Guidelines on the use and monitoring of heparin.

BIBLIOGRAPHIC SOURCE(S)
Baglin T, Barrowcliffe TW, Cohen A, Greaves M, British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin. Br J Haematol 2006 Apr;133(1):19-34. [112 references] PubMed

GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

December 3, 2008, Innohep (tinzaparin): The U.S. Food and Drug Administration (FDA) has requested that the labeling for Innohep be revised to better describe overall study results which suggest that, when compared to unfractionated heparin, Innohep increases the risk of death for elderly patients (i.e., 70 years of age and older) with renal insufficiency. Healthcare professionals should consider the use of alternative treatments to Innohep when treating elderly patients over 70 years of age with renal insufficiency and deep vein thrombosis (DVT), pulmonary embolism (PE), or both.

abrir aquí para acceder al documento AHRQ NGC completo:
Guidelines on the use and monitoring of heparin.